These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 34578414)

  • 1. Genetic Subtypes and Natural Resistance Mutations in HCV Genotype 4 Infected Saudi Arabian Patients.
    Di Stefano M; Ismail MH; Leitner T; Faleo G; Elmnan Adem SA; Elamin MOME; Eltreifi O; Alwazzeh MJ; Fiore JR; Santantonio TA
    Viruses; 2021 Sep; 13(9):. PubMed ID: 34578414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Preexisting Hepatitis C Virus Genotype 6 NS3, NS5A, and NS5B Polymorphisms on the
    McPhee F; Ueland J; Vellucci V; Bowden S; Sievert W; Zhou N
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30718256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pooled analysis of HCV genotype 1 resistance-associated substitutions in NS5A, NS3 and NS5B pre-and post-treatment with 12 weeks of daclatasvir, asunaprevir and beclabuvir.
    McPhee F; Hernandez D; Zhou N; Ueland J; Yu F; Vellucci V; Huang X; Wang X; Ishikawa H; Karino Y; Kumada H
    Antivir Ther; 2018; 23(1):53-66. PubMed ID: 28594332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of chronic HCV infection with DAAs in Rio de Janeiro/Brazil: SVR rates and baseline resistance analyses in NS5A and NS5B genes.
    Costa VD; Brandão-Mello CE; Nunes EP; Dos Santos Silva PGC; de Souza Rodrigues LLLX; Lampe E; do Amaral Mello FC
    PLoS One; 2019; 14(5):e0216327. PubMed ID: 31063475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Net emergence of substitutions at position 28 in NS5A of hepatitis C virus genotype 4 in patients failing direct-acting antivirals detected by next-generation sequencing.
    Nguyen T; Akhavan S; Caby F; Bonyhay L; Larrouy L; Gervais A; Lebray P; Poynard T; Calmus Y; Simon A; Valantin MA; Calvez V; Marcelin AG; Todesco E
    Int J Antimicrob Agents; 2019 Jan; 53(1):80-83. PubMed ID: 30236959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HCV genotype-1 subtypes and resistance-associated substitutions in drug-naive and in direct-acting antiviral treatment failure patients.
    Gozlan Y; Ben-Ari Z; Moscona R; Shirazi R; Rakovsky A; Kabat A; Veizman E; Berdichevski T; Weiss P; Cohen-Ezra O; Lurie Y; Gafanovich I; Braun M; Cohen-Naftaly M; Shlomai A; Shibolet O; Zigmond E; Zuckerman E; Carmiel-Haggai M; Nimer A; Hazzan R; Maor Y; Kitay-Cohen Y; Shemer-Avni Y; Kra-Oz Z; Schreiber L; Peleg O; Sierra S; Harrigan PR; Mendelson E; Mor O
    Antivir Ther; 2017; 22(5):431-441. PubMed ID: 28067632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of resistance-associated substitutions to NS3, NS5A and NS5B inhibitors at DAA-failure in hepatitis C virus in Italy from 2015 to 2019.
    Rossetti B; Paglicci L; Di Maio VC; Cassol C; Barbaliscia S; Paolucci S; Bruzzone B; Coppola N; Montagnani F; Micheli V; Monno L; Zanelli G; Santantonio T; Cuomo N; Caudai C; Zazzi M; Ceccherini-Silberstein F; On Behalf Of The Hcv Virology Italian Resistance Network Vironet C
    Infez Med; 2021 Jun; 29(2):242-251. PubMed ID: 34061790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses.
    Welzel TM; Bhardwaj N; Hedskog C; Chodavarapu K; Camus G; McNally J; Brainard D; Miller MD; Mo H; Svarovskaia E; Jacobson I; Zeuzem S; Agarwal K
    J Hepatol; 2017 Aug; 67(2):224-236. PubMed ID: 28343981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies.
    Hezode C; Reau N; Svarovskaia ES; Doehle BP; Shanmugam R; Dvory-Sobol H; Hedskog C; McNally J; Osinusi A; Brainard DM; Miller MD; Mo H; Roberts SK; O'Leary JG; Shafran SD; Zeuzem S
    J Hepatol; 2018 May; 68(5):895-903. PubMed ID: 29221887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a Novel Hepatitis C Virus Genotype From Punjab, India: Expanding Classification of Hepatitis C Virus Into 8 Genotypes.
    Borgia SM; Hedskog C; Parhy B; Hyland RH; Stamm LM; Brainard DM; Subramanian MG; McHutchison JG; Mo H; Svarovskaia E; Shafran SD
    J Infect Dis; 2018 Oct; 218(11):1722-1729. PubMed ID: 29982508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C virus genotype 4 resistance and subtype demographic characterization of patients treated with ombitasvir plus paritaprevir/ritonavir.
    Schnell G; Tripathi R; Beyer J; Reisch T; Krishnan P; Lu L; Dekhtyar T; Hall C; Vilchez RA; Pilot-Matias T; Collins C
    Antimicrob Agents Chemother; 2015 Nov; 59(11):6807-15. PubMed ID: 26282418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Geographic Distribution of HCV-GT3 Subtypes and Naturally Occurring Resistance Associated Substitutions.
    Bagaglio S; Messina E; Hasson H; Galli A; Uberti-Foppa C; Morsica G
    Viruses; 2019 Feb; 11(2):. PubMed ID: 30754682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies.
    Di Maio VC; Cento V; Lenci I; Aragri M; Rossi P; Barbaliscia S; Melis M; Verucchi G; Magni CF; Teti E; Bertoli A; Antonucci F; Bellocchi MC; Micheli V; Masetti C; Landonio S; Francioso S; Santopaolo F; Pellicelli AM; Calvaruso V; Gianserra L; Siciliano M; Romagnoli D; Cozzolongo R; Grieco A; Vecchiet J; Morisco F; Merli M; Brancaccio G; Di Biagio A; Loggi E; Mastroianni CM; Pace Palitti V; Tarquini P; Puoti M; Taliani G; Sarmati L; Picciotto A; Vullo V; Caporaso N; Paoloni M; Pasquazzi C; Rizzardini G; Parruti G; Craxì A; Babudieri S; Andreoni M; Angelico M; Perno CF; Ceccherini-Silberstein F;
    Liver Int; 2017 Apr; 37(4):514-528. PubMed ID: 28105744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir.
    Sarrazin C; Dvory-Sobol H; Svarovskaia ES; Doehle BP; Pang PS; Chuang SM; Ma J; Ding X; Afdhal NH; Kowdley KV; Gane EJ; Lawitz E; Brainard DM; McHutchison JG; Miller MD; Mo H
    Gastroenterology; 2016 Sep; 151(3):501-512.e1. PubMed ID: 27296509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequent Antiviral Treatment Failures in Patients Infected With Hepatitis C Virus Genotype 4, Subtype 4r.
    Fourati S; Rodriguez C; Hézode C; Soulier A; Ruiz I; Poiteau L; Chevaliez S; Pawlotsky JM
    Hepatology; 2019 Feb; 69(2):513-523. PubMed ID: 30125371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance-associated substitutions in patients with chronic hepatitis C virus genotype 4 infection.
    Dietz J; Kalinina OV; Vermehren J; Peiffer KH; Matschenz K; Buggisch P; Niederau C; Schattenberg JM; Müllhaupt B; Yerly S; Ringelhan M; Schmid RM; Antoni C; Müller T; Schulze Zur Wiesch J; Piecha F; Moradpour D; Deterding K; Wedemeyer H; Moreno C; Berg T; Berg CP; Zeuzem S; Welsch C; Sarrazin C;
    J Viral Hepat; 2020 Oct; 27(10):974-986. PubMed ID: 32396998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interim analysis of a 3-year follow-up study of NS5A and NS3 resistance-associated substitutions after treatment with grazoprevir-containing regimens in participants with chronic HCV infection.
    Lahser F; Galloway A; Hwang P; Palcza J; Brunhofer J; Wahl J; Robertson M; Barr E; Black T; Asante-Appiah E; Haber B
    Antivir Ther; 2018; 23(7):593-603. PubMed ID: 30038064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.
    Dietz J; Susser S; Vermehren J; Peiffer KH; Grammatikos G; Berger A; Ferenci P; Buti M; Müllhaupt B; Hunyady B; Hinrichsen H; Mauss S; Petersen J; Buggisch P; Felten G; Hüppe D; Knecht G; Lutz T; Schott E; Berg C; Spengler U; von Hahn T; Berg T; Zeuzem S; Sarrazin C;
    Gastroenterology; 2018 Mar; 154(4):976-988.e4. PubMed ID: 29146520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dissection of two drug-targeted regions of Hepatitis C virus subtype 4a infecting Egyptian patients.
    El-Tahan RR; Ghoneim AM; Zaghloul H
    Virus Genes; 2020 Oct; 56(5):564-581. PubMed ID: 32572756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baseline resistance associated substitutions in HCV genotype 1 infected cohort treated with Simeprevir, Daclatasvir and Sofosbuvir in Brazil.
    Aguiar BF; Campos GRF; Rodrigues JPV; Marques NN; Molina BF; Bittar C; Souza FF; Martinelli ALC; Rahal P; Pereira LRL
    Clin Res Hepatol Gastroenterol; 2020 Jun; 44(3):329-339. PubMed ID: 31523019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.